CPN2 and myasthenia gravis: Also, genetically predicted elevation in circulating PRSS8 abundance is associated with an increased risk of MG (OR = 4.252; 95% CI 2.275–7.945; P = 5.69 × 10–6), as well as heightened risks for both early-onset MG (OR = 8.916; 95% CI 2.558–31.083; P = 5.948 × 10–6) and late-onset MG (OR = 3.477; 95% CI 1.662–7.275; p = 9.379 × 10–4).Conversely, a genetically proxied increase in circulating CPN2 levels demonstrated an association with decreased MG risk (OR = 0.819; 95% CI 0.739–0.908; P = 1.444 × 10−4) and also late-onset MG (OR = 0.798; 95% CI 0.706–0.903; P = 3.282 × 10–04).